{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:25:35Z","timestamp":1768641935185,"version":"3.49.0"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Aims: To report potential vaccine-induced ocular adverse events following inactivated COVID-19 vaccination (Sinopharm and Sinovac). Methods: This case series took place at a tertiary referral center in the southeast of China (Xiamen Eye Center in Fujian Province) from February 2021 to July 2021. Patients who received the first dose of inactivated COVID-19 vaccine and developed vaccine-related ocular adverse events within 10 days were included. The diagnosis of vaccine-related ocular adverse events was guided by the World Health Organization causality assessment and the Naranjo criteria. Results: Ten eyes of seven patients (two male individuals) presenting with ocular complaints following COVID-19 vaccine were included in the study. The mean (SD) age was 41.4 (9.3) years (range, 30\u201355 years). The mean time of ocular adverse event manifestations was 4.9 days (range, 1\u201310 days). Three patients were diagnosed with Vogt\u2013Koyanagi\u2013Harada (VKH)-like uveitis, one with multifocal choroiditis, one with episcleritis, one with iritis, and one with acute idiopathic maculopathy. Two patients received the second dose of vaccine. One patient had exacerbation of VKH, and one patient had no symptoms. An aqueous humor analysis in three patients revealed elevated proinflammatory cytokines and negative virus copy. All the patients had transient ocular disturbance and responded well to steroids. No recurrence was noted during 6 months of follow-up. Conclusions: Potential ocular adverse events should be reported to increase the awareness of the health community for timely detection and proper treatment.<\/jats:p>","DOI":"10.3390\/vaccines10030482","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T21:48:42Z","timestamp":1647899322000},"page":"482","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9567","authenticated-orcid":false,"given":"Xiuju","family":"Chen","sequence":"first","affiliation":[{"name":"Xiamen Eye Center, Xiamen University, Xiamen 361005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[{"name":"Xiamen Eye Center, Xiamen University, Xiamen 361005, China"},{"name":"Fujian Key Laboratory of Ocular Surface and Corneal Diseases, Xiamen University, Xiamen 361005, China"},{"name":"People\u2019s Hospital of Peking University, Beijing 100033, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Li","sequence":"additional","affiliation":[{"name":"Xiamen Eye Center, Xiamen University, Xiamen 361005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghan","family":"Li","sequence":"additional","affiliation":[{"name":"Xiamen Eye Center, Xiamen University, Xiamen 361005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songjian","family":"Gong","sequence":"additional","affiliation":[{"name":"Xiamen Eye Center, Xiamen University, Xiamen 361005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"ref_1","unstructured":"Geneva: World Health Organization (2022, February 01). WHO COVID-19 Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","article-title":"China\u2019s COVID vaccines have been crucial\u2014Now immunity is waning","volume":"598","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","unstructured":"Che, Y., Liu, X., Pu, Y., Zhou, M., and Li, Q. (2020). Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamaophthalmol.2021.3477","article-title":"Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi","volume":"139","author":"Pichi","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ng, X.L., Betzler, B.K., Testi, I., Ho, S.L., Tien, M., Ngo, W.K., Zierhut, M., Chee, S.P., Gupta, V., and Pavesio, C.E. (2021). Ocular adverse events after COVID-19 vaccination. Ocul. Immunol. Inflamm.","DOI":"10.1080\/09273948.2021.1976221"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1097\/IAE.0000000000003277","article-title":"Uveitis after the Bnt162b2 Mrna Vaccination Against Sars-Cov-2 Infection: A Possible Association","volume":"41","author":"Rabinovitch","year":"2021","journal-title":"Retina"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijid.2021.07.035","article-title":"Anterior uveitis onset after bnt162b2 vaccination: Is this just a coincidence?","volume":"110","author":"Renisi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Haseeb, A.A., Solyman, O., Abushanab, M.M., Abo Obaia, A.S., and Elhusseiny, A.M. (2022). Ocular Complications following Vaccination for COVID-19: A One-Year Retrospective. Vaccines, 10.","DOI":"10.3390\/vaccines10020342"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","unstructured":"World Health Organization (2003). Drug and Therapeutics Committees: A Practical Guide, World Health Organization. Technical Report."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101404","DOI":"10.1016\/j.ajoc.2022.101404","article-title":"Acute-onset Vogt-Koyanagi-Harada-like uveitis following COVID-19 inactivated virus vaccination","volume":"26","author":"Chen","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/09273948.2020.1734213","article-title":"Presumed unilateral acute idiopathic maculopathy following H1N1 vaccination","volume":"29","author":"Jorge","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jamaophthalmol.2021.3483","article-title":"COVID-19, COVID-19 vaccinations, and subsequent abnormalities in the retina: Causation or coincidence?","volume":"139","author":"Jampol","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40123-021-00415-5","article-title":"The Eye of the Storm: COVID-19 Vaccination and the Eye","volume":"11","author":"Ng","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.27334","article-title":"A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine","volume":"94","author":"Yue","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203316686406","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (Shoenfeld\u2019s syndrome)\u2014An update","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Venkatesh, R., Reddy, N.G., Mishra, P., Gupta, A., Mahendradas, P., and Yadav, N.K. (2022). Unilateral Acute Idiopathic Maculopathy following Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV-2) Infection. Ocul. Immunol. Inflamm.","DOI":"10.1080\/09273948.2022.2028287"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101479","DOI":"10.1016\/j.ajoc.2022.101479","article-title":"Acute idiopathic maculopathy after COVID-19 vaccination","volume":"26","author":"Hasegawa","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/0301-4738.178141","article-title":"Vogt-Koyanagi-Harada syndrome following influenza vaccination","volume":"64","author":"Kim","year":"2016","journal-title":"Indian J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40064-016-2223-4","article-title":"Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis","volume":"5","author":"Dogan","year":"2016","journal-title":"Springerplus"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Koong, L.R., Chee, W.K., Toh, Z.H., Ng, X.L., Agrawal, R., and Ho, S.L. (2021). Vogt-Koyanagi-harada disease associated with COVID-19 mRNA vaccine. Ocul. Immunol. Inflamm.","DOI":"10.1080\/09273948.2021.1974492"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-021-00319-3","article-title":"Vogt-Koyanagi-Harada syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine","volume":"7","author":"Saraceno","year":"2021","journal-title":"Int. J. Retin. Vitr."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:40:31Z","timestamp":1760136031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["vaccines10030482"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10030482","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}